- Home
- COYA vs PROK Comparison
COYA vs PROK Comparison
Compare COYA & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- PROK
- Stock Information
- Founded
- COYA 2020
- PROK 2015
- Country
- COYA United States
- PROK United States
- Employees
- COYA N/A
- PROK N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COYA Health Care
- PROK Health Care
- Exchange
- COYA Nasdaq
- PROK Nasdaq
- Market Cap
- COYA 99.8M
- PROK 85.5M
- IPO Year
- COYA 2022
- PROK N/A
- Fundamental
- Price
- COYA $6.67
- PROK $3.29
- Analyst Decision
- COYA Strong Buy
- PROK Buy
- Analyst Count
- COYA 4
- PROK 5
- Target Price
- COYA $16.50
- PROK $6.25
- AVG Volume (30 Days)
- COYA 88.2K
- PROK 37.8M
- Earning Date
- COYA 08-11-2025
- PROK 08-08-2025
- Dividend Yield
- COYA N/A
- PROK N/A
- EPS Growth
- COYA N/A
- PROK N/A
- EPS
- COYA N/A
- PROK N/A
- Revenue
- COYA $3,685,107.00
- PROK $306,000.00
- Revenue This Year
- COYA $21.49
- PROK $85.21
- Revenue Next Year
- COYA N/A
- PROK N/A
- P/E Ratio
- COYA N/A
- PROK N/A
- Revenue Growth
- COYA N/A
- PROK N/A
- 52 Week Low
- COYA $4.65
- PROK $0.46
- 52 Week High
- COYA $10.24
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- COYA 65.20
- PROK 60.03
- Support Level
- COYA $5.66
- PROK $2.80
- Resistance Level
- COYA $6.07
- PROK $4.05
- Average True Range (ATR)
- COYA 0.32
- PROK 1.11
- MACD
- COYA 0.06
- PROK -0.07
- Stochastic Oscillator
- COYA 88.60
- PROK 37.15
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.